JAK inhibition therapy for intractable cutaneous infectious granulomatosis with unknown etiology: a case report

20260 citationsJournal Articlediamond Open Access

Authors

Suiting Ao · Academy of Medical Sciences

Mingjia Hu · Academy of Medical Sciences

Fanli Xu · Academy of Medical Sciences

Shuang Lyv · Academy of Medical Sciences

F. Zhang · Academy of Medical Sciences

H Liu · Academy of Medical Sciences

Abstract

This case-report highlights a potential role for JAK inhibition, upadacitinib, in managing refractory cutaneous granulomatosis with an excessive immune response despite no identifiable pathogen and pathogen clearance.

Topics & Keywords

Sarcoidosis and Beryllium Toxicity Research Vasculitis and related conditions Cutaneous lymphoproliferative disorders research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Dermatological Treatment

Volume 37, Issue 1, pp. 2637510-2637510

DOI: 10.1080/09546634.2026.2637510

Field-Weighted Citation Impact: 0.00